Though there is no defined treatment, researchers are hunting for several antivirals or other pharmaceutical agents to reduce the viral load and to improve immunity in patients with COVID-19. Several clinical trials have studied the safety and efficacy of various pharmaceutical agents. Remedesivir is one of the most effective antivirals among the available drugs. However, it is being used only in hospitalized patients and not for those who have mild or moderate symptoms.
Researchers from UT Austin’s Division of Molecular Pharmaceutics and Drug Delivery, University of Texas, Austin, have now developed remdesivir in a dry powder formulation . Thin-film freezing technology was used to make the powdered form. This formulation can be used in inhalers to tackle the COVID-19 infection in its early stages, directly in the lungs. The advantages of using dry powdered remdesivir includes:…
